Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients

Thyroid

Volumn 20, Issue 11, 2010, Pages 1247-1252

  Rosario, Pedro Weslley ^a,b   Xavier, Arthur Cezar Malard ^a   Calsolari, Maria Regina ^b  

^a Postgraduation Program   (Brazil)

^b Endocrinology Service   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

ADULT; AGE; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; GENDER; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TUMOR ABLATION; WHOLE BODY SCINTISCANNING;

ABLATION TECHNIQUES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RISK; THYROID HORMONES; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 78249232029     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0114     Document Type: Article

References (37)

1. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803.
2. Maia AL, Ward LS, Carvalho GA, Graf H, Maciel RM, Maciel LM, Rosário PW, Vaisman M 2007 Thyroid nodules and differentiated thyroid cancer: Brazilian consensus. Arq Bras Endocrinol Metabol 51:867-893.
3. Paz-Filho GJ, Graf H 2008 Recombinant human thyrotropin in the management of thyroid disorders. Expert Opin Biol Ther 8:1721-1732.
4. Biondi B, Pulcrano M, Pagano L, Lombardi G 2009 Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer. Biologics 3:9-13.
5. Wartofsky L 2009 Highlights of the American Thyroid Association Guidelines for patients with thyroid nodules or differentiated thyroid carcinoma: the 2009 revision. Thyroid 19:1139-1143.
6. Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, Omry G, Larson S 2010 Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 20:257-263.
7. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Cipri C, Pacini F 2007 A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542-3546.
8. Rosario PW, Borges MA, Purisch S 2008 Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 49:1776-1782.
9. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638-1644.
10. Rosario PW, Barroso AL, Rezende LL, Padrão EL, Borges MA, Guimarães VC, Purisch S 2006 Testicular function alter radioiodine therapy in patients with thyroid cancer. Thyroid 16:667-670.
11. Souza-Rosario PW, Alvarenga-Fagundes T, Villasboas Fagundes AS, Barroso AL, Lamego Rezende L, Lanza Padrão E, Guimarães VC, Horta AC, Franco M, Purisch S 2005 Ovarian function after radioiodine therapy in patients with thyroid cancer. Exp Clin Endocrinol Diabetes 113:331-333.
12. Rosario PW, Maia FF, Barroso A, Padrao EL, Rezende L, Purisch S 2004 Sialoadenitis following ablative therapy with high doses of radioiodine for treatment of differentiated thyroid cancer. Arq Bras Endocrinol Metabol 48:310-314.
13. Frigo A, Dardano A, Danese E, Daví MV, Moghetti P, Colato C, Francia G, Bernardi F, Traino C, Monzani F, Ferdeghini M 2009 Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. J Clin Endocrinol Metab 94:3472-3476.
14. Borget I, Remy H, Chevalier J, Ricard M, Allyn M, Schlumberger M, De Pouvourville G 2008 Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 35:1457-1463.
15. Pitoia F, Ward L, Wohllk N, Friguglietti C, Tomimori E, Gauna A, Camargo R, Vaisman M, Harach R, Munizaga F, Corigliano S, Pretell E, Niepomniszcze H 2009 Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol 53:884-887.
16. Molinaro E, Viola D, Passannanti P, Agate L, Lippi F, Ceccarelli C, Pinchera A, Elisei R 2009 Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy. Q J Nucl Med Mol Imaging 53:490-502.
17. Rosario PW, Fagundes TA, Rezende LL, Padrao EL, Borges MA, Barroso AL 2006 Assessing hypothyroidism in the preparation of patients with thyroid cancer: cardiovascular risk, renal function, drug metabolism, persistence of elevated thyroid-stimulating hormone, and absence from work. Endocrinologist 16:25-29.
18. Rosario PW, Fagundes TA, Purisch S, Padrao EL, Rezende LL, Barroso AL 2005 Recombinant TSH in ablative therapy and follow-up of patients with differentiated thyroid carcinoma. Arq Bras Endocrinol Metabol 49:350-358.
19. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G 2003 Radioiodine treatment with 30mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88:4110-4115.
20. Pacini F, Ladenson P, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932.
21. Zulewski H, Müller B, Exer P, Miserez AR, Staub JJ 1997 Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab 82:771-776.
22. Rosario PW, Faria S, Bicalho L, Gatti Alves MF, Borges MAR, Purisch S, Padrão EL, Rezende LL, Barroso AL 2005 Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 24:1385-1389.
23. Rosario PW, Tavares Júnior WC, Biscolla RP, Purisch S, Maciel RM 2007 Usefulness of neck ultrasonography in the follow-up of patients with differentiated thyroid cancer. Arq Bras Endocrinol Metabol 51:593-600.
24. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM 2002 Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 87:3242-3247.
25. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-3673.
26. do Rosário PW, Borges MA, Alves MF, Purisch S, Padrão EL, Rezende LL, Barroso AL 2006 Follow-up of high-risk patients with differentiated thyroid cancer without persistent disease after initial therapy. Arq Bras Endocrinol Metabol 50:909-913.
27. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Turco A, Mariani G 2006 Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun 27:627-632.
28. Chianelli M, Todino V, Graziano F, Panunzi C, Pace D, Guglielmi R, Signore A, Papini E 2009 Low dose (2.0GBq; 54mCi) radioiodine postsurgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low risk patients. Eur J Endocrinol 160:431-436.
29. 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063-4068.
30. Täieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry J, Mundler O 2009 Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation with recombinant human thyrotropin: a randomized controlled study. Clin Endocrinol (Oxf) 71:115-123.
31. Emmanouilidis N, Müller J, Jäger M, Kaaden S, Helfritz F, Güner Z, Kespohl H, Knitsch W, Knapp WH, Klempnauer J, Scheumann GF 2009 Surgery and radio ablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human thyrotropin. Eur J Endocrinol 161:763-769.
32. Pitoia F, Tamer E, Salvai ME, Niepomniszcze H 2009 Protocol for thyroid remnant ablation after recombinant TSH in thyroid carcinoma. Medicina (Buenos Aires) 69:148-152.
33. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS 2010 Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 20:173-179.
34. Tala Jury HP, Castagna MG, Fioravanti C, Cipri C, Brianzoni E, Pacini F 2010 Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab 95:230-237.
35. Barbaro D, Grosso M, Boni G, Lapi P, Pasquini C, Orsini P, Turco A, Meucci G, Marzola MC, Berti P, Miccoli P, Mariani G, Rubello D 2009 Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium. Eur J Nucl Med Mol Imaging 37:242-249.
36. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ 2008 Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49:764-770.
37. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648-654.